Sangamo Therapeutics, Inc.
SGMO
$0.5863
$0.01312.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 34.68% | -30.78% | -319.23% | 129.54% | 26.40% |
| Total Depreciation and Amortization | -1.40% | -9.88% | 0.38% | -17.33% | 1.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13.26% | 1.09% | -25.03% | -48.45% | 23.19% |
| Change in Net Operating Assets | -2,919.48% | -100.50% | 442.96% | -32,042.86% | 100.19% |
| Cash from Operations | 30.56% | -680.33% | -128.50% | 143.74% | 44.75% |
| Capital Expenditure | -- | -- | -32.17% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | 324.14% | 174.02% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Investing | -- | -- | 468.24% | 83.46% | -99.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 180.22% | 43.68% | -- | -- | -- |
| Repurchase of Common Stock | 81.14% | -912.27% | -8.37% | 61.91% | -32.59% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 251.78% | 16.35% | 3,543.84% | 61.91% | -102.41% |
| Foreign Exchange rate Adjustments | 113.94% | 156.83% | -299.56% | 538.13% | 61.64% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 178.65% | -716.05% | -78.96% | 146.88% | -419.24% |